Harvard Bioscience
HBIO
65 hedge funds and large institutions have $127M invested in Harvard Bioscience in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 25 reducing their positions, and 7 closing their positions.
300% more call options, than puts
Call options by funds: $8K | Put options by funds: $2K
62% more capital invested
Capital invested by funds: $78.5M → $127M (+$48.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.06% less ownership
Funds ownership: 7.22% → 7.16% (-0.06%)
4% less funds holding
Funds holding: 68 → 65 (-3)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
44% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.44M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$1.03M |
| 3 |
2C
272 Capital
Dallas,
Texas
|
+$657K |
| 4 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$544K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$481K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
-$593K |
| 2 |
HP
Harvey Partners
Tarrytown,
New York
|
-$590K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$301K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$259K |
| 5 |
D.E. Shaw & Co
New York
|
-$237K |
HBIO Hedge Fund Activity: Q1 2023 in Review
65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2023, worth a combined $127M — up 62% from $78.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of HBIO and 6 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 14 added.
The largest buyer was Vanguard Group, adding an estimated $1.44M. The largest seller was AMH Equity, cutting an estimated $593K.
- 65 institutional investors held Harvard Bioscience (HBIO) as of Q1 2023, down from 68 in Q4 2022.
- Funds reported $127M of Harvard Bioscience stock for Q1 2023, up 62% quarter-over-quarter.
- 6 funds opened new Harvard Bioscience positions in Q1 2023 and 7 closed out, a net change of -1 holder.
- The largest Harvard Bioscience buyer in Q1 2023 was Vanguard Group, an estimated $1.44M added.
- The largest Harvard Bioscience seller in Q1 2023 was AMH Equity, an estimated $593K sold.
Based on aggregated 13F filings for Q1 2023.